MedTrace Logo

Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections

NCT00207753 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2005-11-17

No results posted yet for this study

Summary

The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.

Conditions

  • Ascariasis
  • Trichuriasis
  • Hookworm Infection
  • Strongyloidiasis
  • Pediculosis

Interventions

DRUG

albendazole vs. combined albendazole/ivermectin treatment

Sponsors & Collaborators

Principal Investigators

  • Michael J Beach, Ph.D. · Centers for Disease Control and Prevention

  • Byron Arana, MD · MERTU/CDC-Universite de Valle de Guatemala

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Completion
2005-03-31

Countries

  • Guatemala

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207753 on ClinicalTrials.gov